Upcoming Events AMCARE and DRIVE Winter School
November 28th - December 1st , Galway Bay Hotel, Salthill, Galway, Ireland
EC-funded projects AMCARE and DRIVE are at the cutting edge of advanced therapies and are characterised by strong partnerships between academic researchers and high-tech industrial partners capable of navigating the legal, regulatory and manufacturing obstacles to effect ATMP protection, approval, scale-up and distribution to the marketplace (read more).
Attended Events DRIVE's Patient Panel
At the DRIVE Patient Panel in Dublin diabetes patients or parents/spouses of diabetes patients discussed the potential risks, benefits, challenges and opportunities for DRIVE’s β-System diabetes reversing implant technology with scientific and medical experts from the DRIVE Consortium.
Patient comments, opinion and suggestions for improvement to the technology are summarised in the Patient Panel report (download here).
Safeguarding the delivery of pancreatic islets for the treatment of diabetes
DRIVE aims to improve pancreatic islet transplant therapy for diabetes mellitus, a chronic disease characterised by high blood sugar due to a shortage of insulin. Transplant of insulin-producing pancreatic islets restores tight natural control of blood sugar, eliminating the need for multiple daily injections of insulin, that ultimately affect patient’s quality of life.
Despite its proven effectiveness among current treatments for diabetes, this therapy, which involves infusing purified human pancreatic islets from donor pancreases into the patient’s liver, suffers from poor survival and engraftment of transplanted islets in the hostile liver environment. As a result, multiple donor pancreases are necessary for a successful islet transplant, which limits the use of this therapy to a small percentage of “brittle” type 1 patients for whom daily insulin injections are not sufficient to control their diabetes.
DRIVE will also develop a minimally invasive injection catheter (“β-Cath”) and perform a series of pre-clinical studies on the integrated β-Gel/β-Shell/β-Cath system to assess its efficacy in vivo.